SOURCE: Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc.

August 09, 2016 08:30 ET

Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2016 Financial Results

THE WOODLANDS, TX--(Marketwired - Aug 9, 2016) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended June 30, 2016 after the close of trading on Thursday, August 11th. The Company will also conduct a conference call and webcast to discuss financial results and provide a corporate update at 4:30 P.M. ET on Thursday, August 11th

Conference Call and Webcast Details

To listen to the conference call, dial in approximately ten minutes before the scheduled 4:30 P.M. time to 201-689-8040 or toll free at 877-407-8133. The conference ID number is 13642247.

A live webcast of the call can also be accessed here or via the webcast link on the Investor Relations page of Opexa's website ( An archive of the webcast will be available on the Company's website until November 11, 2016.

There will be a brief Question & Answer session following management commentary. 

About Opexa

Opexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient. Top-line results from the Abili-T trial are expected in early 4th quarter of 2016.

For more information, visit the Opexa Therapeutics website at or follow company news on Twitter via @OPEXACEO or LinkedIn.

Contact Information